Development code · Small Molecule

RP-5063

RP-5063 is a development code for Brilaroxazine (RP5063), developed by Reviva Pharmaceuticals Holdings, Inc..

Status: Phase 3 for Schizophrenia
Mechanism: D2 Partial agonist
Developer: Reviva Pharmaceuticals Holdings, Inc.

Programs

Brilaroxazine (RP5063) for SchizophreniaPhase 3Active

Also known as

RP5063
brilaroxazine
oxaripiprazole
1239729-06-6
6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one

View the full Brilaroxazine (RP5063) profile →